

The use of andexanet alpha in the Polish setting: An interdisciplinary protocol Expert consensus statement of the Polish Cardiac Society

Ewelina Kazimierczyk¹, Milena Dąbrowska², Marek Gierlotka³,
Katarzyna Kapica-Topczewska⁴, Bartosz Karaszewski⁵, Adam Kobayashi⁶,
Zbigniew Krasiński⁷, Jacek Kubica⁸, Alina Kułakowska⁴, Krzysztof Kurek⁹,
Robert Ładny¹⁰, Eliza Pleban¹¹, Konrad Rejdak¹², Grażyna Rydzewska¹³,
Agnieszka Słowik¹⁴, Piotr Szopiński¹¹, Arkadiusz Woźniak¹⁵, Agnieszka Tycińska¹

Reviewers: Anetta Undas¹⁶, Ewa Straburzyńska-Migaj¹⁷

¹Department of Cardiology, University Clinical Hospital in Białystok, Białystok, Poland

²Department of Hematology Diagnostic, University Clinical Hospital in Białystok, Białystok, Poland

³Department of Cardiology, University Clinical Hospital in Opole, Opole, Poland

⁴Department of Neurology and Stroke Unit, University Clinical Hospital in Białystok, Białystok, Poland

⁵Department of Neurology, Medical University of Gdansk, Gdańsk, Poland

⁶Department of Pharmacology and Clinical Pharmacology, Institute of Medical Sciences, Faculty of Medicine — Collegium Medicum, Cardinal Stefan Wyszyński University in Warsaw, Warszawa, Poland

⁷Department of Vascular, Endovascular, Angiology and Phlebology Surgery (CNWA), Poznan University of Medical Sciences, Poznań, Poland

⁸Department of Cardiology and Internal Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland

⁹Department of Gastroenterology and Internal Medicine, University Clinical Hospital in Białystok, Białystok, Poland

¹⁰1st Clinic of General and Endocrine Surgery, University Clinical Hospital in Białystok, Białystok, Poland

¹¹Vascular Surgery Clinic, Cardinal Stefan Wyszyński National Institute of Cardiology in Warsaw, Warszawa, Poland

¹²Department of Neurology, Medical University of Lublin, Lublin, Poland

¹³Department of Internal Medicine and Gastroenterology and Subdivision of Inflammatory Bowel Diseases of the Ministry of Internal Affairs and Administration in Warsaw, Warszawa, Poland

¹⁴Clinical Department of Neurology, University Hospital in Krakow, Kraków, Poland

¹⁵Department of Vascular Surgery, University Clinical Hospital in Białystok, Białystok, Poland

¹⁶Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland

¹⁷1st Department of Cardiology, Poznan University of Medical Sciences, Poznań, Poland

Correspondence to:

Ewelina Kazimierczyk, MD, PhD,
Department of Cardiology,
University Clinical Hospital
in Białystok,
M Skłodowskiej-Curie 24A,
15-276 Białystok, Poland
phone: +48 85 831 86 56,
e-mail: e-kazimierczyk@wp.pl

Copyright by the Polish Cardiac
Society, 2024

DOI: 10.33963/v.kp.98059

Received:

October 20, 2023

Accepted:

October 20, 2023

Early publication date:

October 31, 2023

ABSTRACT

Andexanet alfa (AA) is a recombinant inactive analog of human activated factor X (FXa), effectively reversing the effects of its inhibitors — rivaroxaban and apixaban, which are available in Poland. The drug was approved for clinical use registration after the publication of the results of the AN-NEXA-4 trial (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of FXa Inhibitors 4), in which its efficacy in restoring hemostasis in life-threatening hemorrhages in patients receiving using the aforementioned anticoagulants was demonstrated. Hence, AA is now recommended for patients on apixaban or rivaroxaban therapy with massive and uncontrollable hemorrhages, including hemorrhagic strokes (HS) and gastrointestinal bleeding.

Drug-specific chromogenic anti-Xa assays are generally best suited for estimating rivaroxaban and apixaban plasma levels, aside from direct assessment of their concentrations. The absence of anti-Xa activity, determined using these assays, allows us to rule out the presence of clinically relevant plasma concentrations of any FXa inhibitor. On the other hand, the dose of AA should not be modified based on the results of coagulation tests, as it depends solely on the time that elapsed since the last dose of FXa inhibitor and on the dose and type of FXa inhibitor.

AA is administered as an intravenous (*i.v.*) bolus, followed by an *i.v.* infusion of the drug. The maximum reversal of anti-Xa activity occurs within two minutes of the end of the bolus treatment, with the continuation of the continuous *i.v.* infusion allowing the effect to be maintained for up to two hours afterwards. Because anticoagulant activity can reappear after the infusion is completed, it is currently unclear at what point after AA administration FXa inhibitors or heparin should be re-administered. In Poland AA is starting to become available and its urgent need to administer it to patients with severe bleeding on apixaban or rivaroxaban.

Key words: andexanet alfa, antidote, apixaban, bleeding, non-vitamin K antagonist oral anticoagulants, rivaroxaban

INTRODUCTION

In recent years, non-vitamin K antagonist oral anticoagulants (NOACs) or direct oral anticoagulant inhibitors (DOACs) have mostly replaced vitamin K antagonists (VKAs) due to their efficacy, safety, and predictable therapeutic effects. The use of NOACs, compared to VKAs, is associated with a lower risk of minor, clinically significant hemorrhages, as well as major hemorrhages, including those resulting in death. However, there is a greater risk of gastrointestinal bleeding in patients taking NOACs, probably due to the presence of the active NOAC in the gastrointestinal tract.

Due to the increasing number of users of NOAC, we encounter them more frequently among trauma patients and those referred to surgical wards. The presence of overt acute bleeding, or the need for immediate surgical intervention, necessitate reversing the anticoagulant effects of previously taken medications. Up until recently, for in-hospital use, the only available drug of this type was idarucizumab that reverses the activity of dabigatran. In recent years, a product that reverses the action of activated factor X (FXa) inhibitors, such as rivaroxaban and apixaban, has just started to become available in clinical practice. In Poland after successful randomized clinical trials. That product is a recombinant, modified, and inactive analog of FXa — andexanet alfa (AA) [1, 2].

FXA INHIBITOR ACTION MECHANISMS

The use of NOACs is effective, safe, and recommended in:

- prevention of stroke and peripheral embolism in patients with established permanent or paroxysmal atrial fibrillation;
- treatment and prevention of venous thromboembolism (VTE).

The NOACs available in Poland include dabigatran, a thrombin inhibitor, and FXa inhibitors, namely rivaroxaban and apixaban. FXa inhibitors are selective direct inhibitors of FXa, which catalyzes the conversion of prothrombin to thrombin, with the effect of the drugs directly proportional to their concentration. The bioavailability of rivaroxaban is 80%–100%, with a half-life of 7–11 hours, while that of apixaban is 50% and 12 hours, respectively. Both drugs are excreted in one-third by the kidneys in an unchanged form, while two-thirds are metabolized by CYP3A4. Unlike dabigatran, FXa inhibitors show a higher percentage of plasma protein binding, hence dialysis does not significantly reduce the concentration of these drugs [3, 4].

One of many significant advantages of NOACs is the lack of need for routine monitoring of blood clotting parameters, as is the case with VKA therapy. However, it is important to remember that these drugs significantly affect the results of most coagulation tests (Table 1). Routine monitoring of plasma NOAC concentrations for dosage

Table 1. The influence of NOACs on hemostasis results

Test	Dabigatran	Rivaroxaban	Apixaban	Comments
A. Routine testing (screening for NOAC)				Interference vs. measurement
PT	-/↑	↑/↑↑	-/↑	Different reagents show different sensitivity; order of sensitivity: rivaroxaban > dabigatran > apixaban; only a few reagents are sensitive to apixaban
APTT	↑/↑↑	-/↑	-/↑	Different reagents show different sensitivity; order of sensitivity: dabigatran > rivaroxaban > apixaban
B. Quantitative tests (measurement of NOAC concentration)				
dTT/DTI	↑↑	-	-	Tests sensitive to dabigatran; insensitive to anti-Xa inhibitors
ECT/ECA	↑↑	-	-	Tests sensitive to dabigatran; insensitive to anti-Xa inhibitors
Anti-Xa	-	↑↑	↑↑	Insensitive to dabigatran. Sensitive to anti-Xa inhibitors

Based on: Favaloro E, Lippi G. *Blood Transfus.* 2017; 15(6): 491–494

Abbreviations: APTT, activated partial thromboplastin test; dTT, diluted thrombin time; ECT, ecarin clotting time; ECA, ecarin chromogenic assay; PT, prothrombin time; TGA, thrombin generation assay; TT, thrombin time

Table 2. Non-vitamin K antagonist oral anticoagulant dosage for stroke prevention in patients with atrial fibrillation

	Rivaroxaban	Apixaban	Dabigatran
Standard dose	20 mg 1 × per day	5 mg 2 × per day	150/110 mg 2 × 1
Reduced dose	15 mg 1 × per day *Dose reduction at CrCl ≤15–49 ml/min	2.5 mg 2 × per day *Dose reduction when 2 of these criteria are met: 1. body weight ≤60 kg, 2. age ≥80 years, 3. serum creatinine level ≥133 μmol/L (1.5 mg/dl), or based on a single criterion: when CrCl 15–29 ml/min	110 mg 2 × 1, if: age ≥80 years, a patient treated with concurrent verapamil, increased risk of gastrointestinal bleeding

Based on: [1]

Abbreviation: CrCl, creatinine clearance

Table 3. Treatment of deep vein thrombosis and pulmonary embolism

	Rivaroxaban	Apixaban	Dabigatran
Initial treatment	15 mg 2 × per day for 21 days	10 mg 2 × per day for 7 days	UFH or LMWH
Continued treatment	20 mg 1 × per day (without dose reduction, unless the risk of bleeding outweighs the risk of recurrent thromboembolism)	5 mg 2 × per day (without dose reduction)	150 mg 2 × 1 (without dose reduction)
Prolonged anticoagulant treatment after pulmonary embolism in patients without malignancies (after 6 months of anticoagulant treatment at therapeutic doses) — recommendation class IIa	10 mg 1 × per day	2.5 mg 2 × per day	150 mg 2 × 1 (dose reduction criteria as in AF)

Based on: [1]

Abbreviations: AF, atrial fibrillation; LMWH, low-molecular-weight heparin; UFH, unfractionated heparin

adjustment is not recommended, as it has not yet been investigated if such an approach has any positive effects on outcomes of long-term treatment. The dosage of most FXa inhibitors is currently determined solely by the indication for their use and renal function while dosing apixaban is additionally determined by the patient's age and weight. The recommended dosages for each clinical indication are shown in Tables 2 and 3 [1, 5].

ROLE OF BIOCHEMICAL EXAMINATIONS IN ASSESSING INDICATIONS FOR TIMING OF ANDEXANET ALFA ADMINISTRATION

At 2–3 hours (±1) after NOAC administration, both the plasma drug concentration and the effects on coagulation parameters are at their highest. Unfortunately, routine determination of baseline coagulation parameters does not accurately assess anticoagulant effect and adherence to drug intake recommendations, let alone the time elapsed since the last drug dose.

In the event of bleeding in patients treated with FXa inhibitors, in addition to routine laboratory tests (blood count, activated partial thromboplastin time [APTT], prothrombin time [PT], fibrinogen, aminotransferases, and creatinine clearance), evaluation of plasma drug levels is advised, and immediate action should be taken as dictated by clinical evaluation, without waiting for laboratory test results.

Based on the results of observational studies, the International Commission for Standardization in Hematology, in its 2021 recommendations, has expanded the indications in which NOAC measurements may be useful to determine appropriate strategies to reverse the anticoagulant effects of the drugs and/or required dosing and to guide further treatment. Urgent indications for laboratory evaluation of NOAC levels generally include se-

vere bleeding, urgent surgery, and acute ischemic stroke, with consideration of thrombolysis. Planned indications for such evaluations are helpful in the long-term care of patients with extreme weight, renal/liver disease, suspected malabsorption syndrome, or drug interactions. Tests evaluating NOACs (over a wide range of concentrations) are covered by most international external quality control programs. Despite lack of standardization, good correlations between different testing systems were demonstrated, with rivaroxaban and apixaban assays showing low coefficients of variation.

The minimum NOAC concentration that can contribute to bleeding is not known. Expert-based guidelines from the International Society on Thrombosis and Haemostasis (ISTH) suggest considering NOAC reversal in patients with severe bleeding and NOAC concentrations >50 ng/ml, and in preoperative patients at high risk of bleeding and NOAC concentrations >30 ng/ml [1, 6–8].

Methods for evaluating the anticoagulant activity of FXa inhibitors

While routine clotting times (PT and APTT) cannot be used to accurately assess the effect of rivaroxaban and apixaban, both clotting times are prolonged in the presence of anti-Xa inhibitors in a drug type- and dose-dependent manner. However, these test results do not demonstrate sufficient linearity, are not very accurate, and depend on the sensitivity of the reagents and the type of coagulometer. PT is considered only as a screening test for the use of rivaroxaban, which, with adequate sensitivity, will result in PT prolongation at the time of therapeutic drug concentration. On the other hand, this parameter should not be used to assess the concentration of apixaban, since in this case, PT prolongation can only occur at the maximum

concentration. It is also worth mentioning that the result of the assay depends on the reagent used. Thus, a normal PT does not necessarily exclude a therapeutic concentration of rivaroxaban, let alone apixaban. Hence, we should not rely on the PT result in the course of clinical management.

The usefulness of POCTs (point-of-care tests) for assessing NOAC activity (including thromboelastography/thromboelastometry, surface acoustic wave, dry blood spot and microsampling techniques, and urine strip tests) has not been confirmed. The tests show low sensitivity at low NOAC concentrations, while urine determinations do not correlate with plasma drug concentrations. Currently, none of the POCT methods meet the parameters of *in vitro* device clinical trials, as they use an animal model or data from a small sample of patients, including a limited number of patients on NOACs, or are based on NOAC-enriched blood *in vitro*. Portable analyzers designed to monitor VKA treatment also do not accurately reflect the coagulation parameters in patients treated with NOACs. Research to implement rapid NOAC testing is still ongoing.

According to the literature, the most clinically useful method to determine the concentration of rivaroxaban and apixaban is the chromogenic "anti-Xa" method, adjusted using drug-specific calibrators. The method is simple to perform, has adequate sensitivity, a wide range of linearity, and a good correlation with NOAC reference mass spectrophotometry methods. Until recently, the anti-Xa method was considered highly specialized and relatively expensive. Today, due to the availability of commercial reagent kits, it can be performed around the clock using virtually any coagulation analyzer, with the result available in 30–60 minutes. The method relies on adding a reagent with a high concentration of FXa to citrated plasma. Factor Xa binds to the FXa inhibitor present in the patient's plasma, and the "free" FXa remaining in the reaction mixture is measured using the amidolytic chromogenic method. The reaction with the chromogenic substrate produces a yellow product (p-nitroaniline), and the measured increase in optical density is inversely proportional to the NOAC concentration. The results are read from a calibration curve plotted using a reagent of known concentration. The test shows a strong correlation with serum concentrations of rivaroxaban and apixaban, hence, it can be used as a clinically reliable monitoring tool. The absence of anti-Xa activity determined using these assays excludes clinically relevant plasma concentrations of the drug. Based on the available literature, it has been determined that anti-Xa activity <0.50 IU/ml corresponds to a plasma concentration of rivaroxaban or apixaban <30 ng/ml, which is the cutoff value for safe undertaking rescue procedures. At the same time, dose adjustment and the use of anticoagulant reversal therapies based on anti-Xa level results are still an area of interest. Firstly, therapeutic ranges have still not been established, and long-term data on the efficacy and safety of interventions targeting the anti-Xa levels are still lacking. Moreover, the value of the anti-Xa index, based

on which we could select a higher or lower AA dose is also unknown. Moreover, in clinical practice, measuring the change of anti-Xa activity is also not useful for predicting clinical response following AA administration. In fact, the results of the ANNEXA-4 study showed no significant relationship between hemostatic efficacy and reduction in anti-Xa activity [1, 2, 6, 8, 9].

Conclusions

Quantitative NOAC measurements may be useful in detecting overexposure to these drugs with a risk of bleeding (also in terms of drug reversal strategies), under-exposure to NOACs with a risk of thrombosis, and identification of drug interactions, which should be confirmed by studies in larger cohorts. The fact that personalized NOAC dosing can improve the benefit-risk ratio in some patients has been confirmed by high inter-individual variability observed in phase III clinical trials, and numerous factors affecting pharmacokinetics and the dose-response relationship.

At present, it is believed that drug-specific chromogenic anti-Xa assays are the most suitable tools for measuring NOAC plasma concentrations. The cost of performing an anti-Xa test (about 100 PLN) is higher than PT/APTT, but comparable to many specialized coagulation tests. Given that their use is limited to specific situations, the burden on healthcare systems should be lower than that currently incurred when treating patients using VKAs.

In Poland, only a handful of laboratories undertake measurement of anti-Xa activity, to the disadvantage of patients in whom NOAC measurement is indicated, especially considering the limitations of the analytical and clinical value of screening tests. With assay automation and the availability of stable, liquid reagents, as well as the increasing use of NOACs, laboratories should enable clinicians to measure concentrations of these drugs. They should also define the sensitivity of measurement systems and participate in international quality control programs that include assessing the impact of NOACs on quantitative and qualitative hemostasis diagnostic tests.

There is a need to establish target therapeutic ranges and standardize NOAC assays, which will improve the safety of these drugs and ensure inter-laboratory reproducibility of results.

Increasing the availability and performance of NOAC concentration assays is essential for the development and implementation of guidelines for the optimal management of patients treated with NOACs as well as for determining strategies for administration and monitoring of the effects of reversal agents for these drugs.

To date, neither the NOAC concentration nor the anti-Xa index value, based on which we could select a higher or lower AA dose, is known. Therefore, in most cases of unknown timing of the last NOAC dose, such as in unconscious patients, it is recommended to administer a higher dose (if the patient is continuously taking 20 mg of rivaroxaban and 5 mg of apixaban) or a lower dose of the drug (patients

continuously treated with a reduced dose of rivaroxaban and apixaban).

ANDEXANET ALFA

Registered and unregistered indications

Andexanet alfa is a recombinant inactive human FXa analog that, through non-specific binding, prevents the action of all known FXa inhibitors, including low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH).

AA is registered for use in patients with serious or life-threatening bleeding, treated with apixaban or rivaroxaban. The efficacy and safety of AA have been confirmed in numerous studies. Initially, the effect was evaluated in animal models [10, 11], followed by a phase II study using different doses of the drug in healthy volunteers receiving FXa inhibitors, to establish a dosing regimen [12, 13]. The effects of bolus administration and i.v. infusion of AA on apixaban and rivaroxaban concentrations, anti-Xa activity, and thrombin

generation were documented in two phase III studies, ANNEXA-A for apixaban and ANNEXA-R for rivaroxaban [14]. In the end, AA was approved after the publication of the results of the ANNEXA-4 trial, a multicenter prospective open-label study that recruited 352 patients who experienced acute major bleeding, mainly intracranial and gastrointestinal, treated with FXa inhibitors. Primary endpoints included the percentage change in anti-FXa activity and the percentage of participants who achieved a good or excellent hemostatic effect within 12 hours after the infusion [2].

Based on the available literature, it is also known that AA administration can be considered off-label in life-threatening clinical situations requiring urgent surgical intervention [1, 15, 16].

Dosage regimen and pharmacokinetics

Low dose: Initial i.v. bolus of 400 mg (at 30 mg/min, about 15 min), then continuous i.v. infusion of 4 mg/min over 120 min (480 mg)




Figure 1. Dosage of andexanet alfa (AA) when using apixaban (based on: [17])




Figure 2. Dosage of andexanet alfa (AA) when using rivaroxaban (based on: [17])

High dose: initial intravenous bolus of 800 mg (at 30 mg/min, approx. 30 min), then continuous i.v. infusion of 8 mg/min over 120 min (960 mg).

The choice of AA dose depends on the dose of FXa inhibitor administered and the time that elapsed since the last dose (Figures 1 and 2). Maximum reversal of anti-Xa activity occurs within two minutes of the end of the bolus. In contrast, the follow-up continuous i.v. infusion allows the reduction in anti-Xa activity to be maintained for two hours after it ends. Then, the anti-Xa level returns to or exceeds the activity recorded in the placebo group [1, 2, 17].

Treatment monitoring, contraindications, possible side effects

As mentioned, the determination of anti-Xa activity is not applicable for monitoring the reversal of the anticoagulant effect of FXa inhibitors. In fact, commonly available assays are inadequate for determining anti-Xa activity after AA administration. The high dilution of the sample and the reversibility of AA binding to the Xa inhibitor, leading to dissociation of the inhibitor and AA, result in overestimation of anti-Xa activity, which can cause significant underestimation of the drug effect.

Treatment monitoring should be based primarily on clinical parameters, namely assessment of hemostasis or side effects.

Interactions

Given the lack of clinical data on the safety of the combined use of AA and prothrombin complex concentrate (PCC), activated prothrombin complex concentrate (aPCC), recombinant factor VIIa, fresh frozen plasma (FFP) or whole blood, such use should be avoided unless absolutely necessary. Several case series have been published on this topic, with the results highlighting the potentially increased thrombotic risk associated with the use of the AA and PCC combination [18, 19].

The use of AA should also be avoided in the case of planned heparinization during surgery, as it may result in unresponsiveness to heparin. AA, however, has not yet been registered as an antidote to reverse the effects of heparins [20, 21].

In about 10% of patients, non-neutralizing antibodies to AA appear in low concentrations during treatment. However, the clinical consequences of their presence have not been demonstrated.

Contraindications to the use of the drug include hypersensitivity to the active compound or any other components of the formulation and a known allergic reaction to hamster proteins [17].

Side effects

The most common mild side effects are infusion-related reactions such as hot flashes, facial flushing, chest discomfort, or increased sweating.

If such mild side effects are observed, careful monitoring of the patient may suffice. In the case of symptoms of moderate severity, short-term interruption or slowing of the infusion with resumption after discomfort has subsided may be considered. Antihistamine administration may also be considered [17].

The use of AA is associated with significant risk of thrombosis. This complication usually results from the underlying disease that is the basis for NOAC therapy (mainly venous thromboembolism, atrial fibrillation), anticoagulant withdrawal, activation of coagulation in the course of bleeding, frequent bed immobilization during hospitalization, as well as the use of drugs reversing the anticoagulant effect of the FXa inhibitor. AA has an independent procoagulant effect, related to tissue factor pathway inhibitor (TFPI) inhibition. The period of increased risk in AA-treated patients remains unknown, but the described thromboembolic events can occur up to 30 days after infusion. In the ANNEXA-4 study, thromboembolic complications affected 10.4% of patients with a median time of occurrence of 9 days. These included cerebrovascular incidents, deep vein thrombosis, pulmonary embolism, and even acute myocardial infarction. Importantly, these did not occur in any patient after NOAC was restarted. Of the 50 patients who developed thromboembolic complications, 34 either did not resume anticoagulant treatment or suffered from thrombosis before it was resumed.

Hence, it is extremely important to monitor patients for signs or symptoms of thrombosis and to consider resuming anticoagulant treatment as early as possible after a bleeding event. To date, however, there is lack of results from randomized trials regarding the optimal time to re-initiate anticoagulant treatment. The clinical decision should, therefore, be made on an individual basis, considering the benefit-risk ratio [2, 17].

As for laboratory tests, increases in D-dimer and prothrombin fragments 1 + 2 above 2 times the upper normal limit were often observed after AA infusion in healthy subjects. These changes lasted from a few hours to a few days but were not related to the occurrence of thromboembolic complications.

AA exhibits modest renal clearance, and there is no need to adjust the drug dose according to renal and hepatic function. It is rapidly degraded in plasma by endogenous proteases, which results in its relatively short half-life (one hour) [17].

PATIENT POPULATIONS WITH SEVERE BLEEDING AND INDICATIONS FOR ANDEXANET ALFA

Patients with hemorrhagic stroke/hemorrhage to the central nervous system

Stroke is caused by restriction of blood supply to the brain or extravasation of blood and, accordingly, is classified as

ischemic stroke (80%), hemorrhagic stroke (HS) (15%), or subarachnoid stroke (5%). The incidence of HS increases sharply with age and is, therefore, expected to remain high due to population aging, even with improvements in blood pressure treatment [22, 23]. Another growing source of HS is the increasing use of oral anticoagulants for treatment [22, 24]. The incidence of intracranial bleeding associated with oral anticoagulants in phase III trials (comparing NOACs with warfarin and aspirin therapy) ranged from 0.2 to 0.5 per 100 person-years. It is worth noting, however, that the risk of such a complication during NOAC treatment is still about twice as low as with chronic warfarin therapy [25]. In two multicenter randomized trials comparing warfarin with rivaroxaban 20 mg daily (ROCKET-AF) or apixaban 2 × 5 mg daily (ARISTOTLE), intracranial hemorrhage incidence was estimated at 0.8% over a median of 707 days of follow-up (0.5/100 person-years) in the ROCKET-AF trial, and 0.33% per year in the ARISTOTLE trial. In comparison, the rates for warfarin treatment were, respectively: 1.2% (0.7/100 person-years) (hazard ratio [HR], 0.67) and 0.8%/year (HR, 0.42) [26, 27].

Known risk factors for intracerebral hemorrhage, despite adequate NOAC therapy, include advanced age, concomitant use of antiplatelet drugs, history of stroke or transient ischemic stroke, history of bleeding, decreased serum albumin levels, thrombocytopenia, race (Asian, Latin American, or black) and, especially, hypertension [25–28].

Hemorrhagic stroke, which occurs more often in patients taking oral anticoagulants, is associated with increased hematoma volume and expansion, as well as increased morbidity and mortality [22, 29]. The mortality rate in HS associated with taking oral anticoagulants is about 60% [30]. The use of NOACs is associated with lower, but still significant, risk of stroke compared with VKAs [31].

There is no doubt that reversal of NOACs should reduce the risk of emergence of hemorrhagic foci. Therefore, therapy should consider the possibility of using fast-acting specific inhibitors of these compounds [22].

The ANNEXA-4 trial showed that 79% of patients with an indication for reversal of factor Xa inhibitors related to HS achieved excellent or good hemostatic efficacy, defined as <35% increase in hematoma volume after 12 hours [2, 32]. Other retrospective studies have shown comparable results of AA hemostatic efficacy, ranging from 64.7 to 88.9% [33–35].

Current retrospective studies or case series have directly compared the risks and benefits of AA and prothrombin complex clotting factor concentrate (PCC) in patients with traumatic and spontaneous intracerebral hematomas (sICH). However, these studies have yielded conflicting results regarding the superiority of any of these medications in achieving hemostasis and decreasing the risk of death or thromboembolic events. Thus, the currently available evidence does not unequivocally support the clinical efficacy of AA or PCC in reversing FXa inhibitor-related acute major

bleeding, nor does it allow for a conventional meta-analysis of potential superiority [36–42]. Further clinical trials are underway that will hopefully clarify the role of each agent in the treatment of sICHs [43].

Hemorrhagic stroke is a complex clinical event requiring multidisciplinary care. A patient with HS taking oral anticoagulants should be provided with medical care including clotting compensation, anticoagulation reversal, intensive blood pressure lowering, and the possibility of neurosurgical intervention, and should be treated in a stroke unit or intensive care unit. Brain imaging is essential to distinguish HS from ischemic stroke and to determine hematoma volume. Computed tomography of the head is the most widely used imaging method for confirming HS due to its widespread availability, speed and ease of performance, and high diagnostic accuracy. Imaging of the brain during the acute phase of HS can provide prognostic information and help monitor the evolution of the focus, development of hydrocephalus, and cerebral edema, especially, in patients whose neurological condition has deteriorated as well as those with impaired consciousness. The therapeutic goal in HS is to minimize the risk of hematoma expansion that results in rapid neurological deterioration. Hematoma expansion tends to occur early (usually within the first 24 hours) and is associated with poor prognosis and mortality. The risk of hematoma expansion is increased in patients taking oral anticoagulants.

In addition, most patients with acute HS have elevated blood pressure, which is also associated with higher risk of hematoma expansion and requires close monitoring.

Therefore, if HS is found to be associated with FXa inhibitor therapy, the use of such drugs should be halted, and efforts should be made to restore clotting function as soon as possible. In these patients, immediate administration of a specific antidote or, possibly PCC, should be considered. Treatment should be administered when clinically significant anticoagulant levels are suspected, based on the type and timing of FXa inhibitor administration. The decision to administer AA is made by the neurologist in conjunction with the neurosurgeon after deciding on conservative or surgical treatment. When considering the use of drugs to restore clotting function, it is important to consider the patient's performance status before HS, the extent of the hemorrhagic focus, the patient's general and neurological condition, and chances of survival. Cost, hospital formulary status, and drug availability may limit the choice of reversal agents, especially in small local hospitals.

The consensus of the European Stroke Organisation recommends immediate reversal of dabigatran anticoagulation with idarucizumab in the case of HS, and immediate administration of AA (grade C) in the case of HS related to factor Xa inhibitors. If AA is not available, high-dose 4-factor PCC (50 IU/kg) is recommended (grade C) [1]. Due to the lack of high-level recommendations for reversal strategies for NOAC-related sICH treatment, further clinical trials are needed. The choice of anticoagulation reversal agents in HS

will continue to evolve, as will our understanding of their efficacy, safety, and risk of thromboembolism.

Patients with gastrointestinal bleeding

The management of patients with gastrointestinal bleeding resulting from overdose/abuse of factor Xa inhibitors is regulated by guidelines of research societies. Since FXa inhibitors, similar to other NOACs, are characterized by a relatively short half-life (12–24 hours), in most cases of gastrointestinal bleeding resulting from their use, temporary withholding of the supply of the preparations in question constitutes sufficient management. The joint 2021 recommendations of the British Society of Gastroenterology (BSG) and the European Society of Gastrointestinal Endoscopy (ESGE) [44] recommend the use of AA (considering its prothrombotic risk) as a reversal agent for factor Xa inhibitors only in hemodynamically unstable gastrointestinal bleeding patients (weak recommendation, low data quality).

Regarding specific sources and etiologies of gastrointestinal bleeding, the ESGE guidelines for upper gastrointestinal (UG) bleeding of non-variceal etiology [45] recommend temporarily withholding anticoagulants, including FXa inhibitors. This management should not delay UG endoscopy. In cases of severe, persistent bleeding, reversal agents should be considered (strong recommendation, low data quality). However, the guidelines refer to agents that reverse the effects of FXa inhibitors, including AA, as compounds of limited availability [46].

The ESGE guidelines for UG bleeding of variceal etiology [47] recommend the use of FXa inhibitor reversal agents exclusively in the absence of hemodynamic stabilization of the patient. The decision to use AA should be made in conjunction with a hematologist, taking into account the risk of thromboembolic complications that may occur as a result of the drug in question (strong recommendation, low-quality data). In other cases, it is recommended that FXa inhibitor therapy be temporarily withheld until its effect ceases on its own.

The ESGE guidelines for lower gastrointestinal bleeding [48] suggest the use of AA for bleeding that persists despite the implementation of endoscopic treatment and for persistent hemodynamic instability of the patient (weak recommendation, low data quality). In such a situation, hemodynamic evaluation of the patient is once more suggested. In addition, the guidelines note the limited availability of the agent, its high cost, and possible complications due to prothrombotic activity [2].

The joint 2022 guidelines of the American College of Gastroenterology (ACG) and the Canadian Association of Gastroenterology (CAG) do not recommend the use of AA in patients with suspected gastrointestinal bleeding resulting from FXa inhibitors (conditional recommendation, very low-quality data) [49]. The above position is based on the very low quality of available literature data (including lack of a control group and methodological inconsisten-

cy in terms of the endoscopic treatment implemented), high costs, and possible side effects of the compound in question. Nevertheless, the ACG and CAG guidelines allow the use of AA in cases of life-threatening gastrointestinal bleeding, in patients who have taken rivaroxaban or apixaban in the prior 24 hours.

Summarizing the recommendations of the scientific societies presented above, in the case of gastrointestinal bleeding resulting from FXa inhibitors, the use of AA is reserved for hemodynamically unstable patients and those with persistent bleeding despite implemented endoscopic treatment. Regardless of the etiology and source of gastrointestinal bleeding, measures to reverse the effects of FXa inhibitors, i.e., administration of AA, should not delay gastrointestinal endoscopy and should be preceded by a hematological consultation.

Patients hospitalized in the Emergency Department

The statutory tasks of the Emergency Department are specified as the delivery of healthcare services, consisting of preliminary diagnosis, and undertaking treatment to the extent necessary to stabilize the vital functions of persons in a state of sudden danger to life or health, from internal or external causes, and in particular in the event of an accident, trauma, and poisoning in adults and children [50]. Among the victims of traffic accidents and patients who have suffered injuries in other circumstances, patients with head injuries are the biggest concern in the Emergency Department. NOAC-associated intracranial hemorrhages are characterized by rapid deterioration of the patient's condition within 24–48 hours, as the hematoma volume increases, while the poor prognosis is related to the extent of the hematoma and intraventricular bleeding. In these cases, rapid reversal of NOAC effects prevents hematoma enlargement and facilitates appropriate surgical intervention. In general, the NOAC should be discontinued, the time of the last dose should be established, and the time of elimination of the drug from the body should be determined. Other measures include evaluation of the morphology, clotting tests, and measurement of creatinine/estimated glomerular filtration rate. A normal hemodynamic compromise should be reached, and if possible, surgery should be postponed, and bleeding should be controlled.

AA should be used in patients taking FXa inhibitors who are victims of traffic accidents, or trauma victims in other circumstances with life-threatening post-traumatic bleeding.

Detailed management of hemorrhagic side effects of FXa inhibitors

Breakdown of bleeding severity and management approaches

The management of bleeding in patients treated with NOACs should be dictated by the severity of bleeding; it

Table 4. Definition of major bleeding in non-surgical patients according to the International Society on Thrombosis and Haemostasis

1	Fatal bleeding and/or
2	Symptomatic bleeding in a critical area or organ (e.g., intraspinal, intracranial, intraocular, articular, pericardial, retroperitoneal, or intramuscular bleeding with fascial compartment syndrome) and/or
3	Bleeding accompanied by a decrease in hemoglobin concentration of ≥ 2 g/dl (or to an absolute concentration of ≤ 8 g/dl with no previous result) or requiring transfusion of ≥ 2 units of whole blood or red blood cell concentrate

Based on: Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. *Thromb Haemost.* 2005; 3: 692–694.

Table 5. BARC — Bleeding Academic Research Consortium scale

0	No bleeding
1	Inactive bleeding, not requiring specialized assistance, which may only contribute to discontinuation of antiplatelet or anticoagulant therapy
2	Overt, active bleeding that does not meet the criteria for types 3–5, but meets one of the three following criteria: 1) requires medical non-surgical intervention; 2) leads to hospitalization; 3) requires immediate evaluation
3	a Overt bleeding associated with a decrease in Hb concentration of 3–5 g/dl or requiring blood transfusion b Overt bleeding associated with a decrease in Hg of ≥ 5 g/dl or cardiac tamponade or bleeding requiring surgical intervention c Intracranial or intraocular bleeding
4	CABG-related bleeding
5	a Probably fatal bleeding (clinical suspicion without confirmation by autopsy or imaging) b Fatal bleeding (overt or confirmed by imaging/autopsy)

Abbreviation: CABG, coronary artery bypass grafting; Hb, hemoglobin

should also be based on the patient's clinical condition and risk factors. To date, numerous scales for assessing the severity of bleeding have been developed, with the most common being the TIMI, ACUITY, and GUSTO scales or the ISTH, frequently used in studies of anticoagulant reversal agents (Table 4). The BARC scale (Bleeding Academic Research Consortium), which is recommended for use in cardiac intensive care units, is a standardized version of these various classifications [51, 52] (Table 5).

Patient-related risk factors include:

- anticoagulant treatment used, including the time that elapsed from the last dose of the drug;
- age;
- renal and hepatic function;
- comorbidities (e.g., coexisting cancer that increases the risk of bleeding or thrombosis);
- drugs that affect NOAC metabolism (this mainly refers to P-gp inhibitors and CYP3A4 inhibitors), concomitant use of antiplatelet drugs and non-steroidal anti-inflammatory drugs (NSAIDs);
- thromboembolic risk, which is important in the context of returning to anticoagulant treatment [1].

The European Society of Cardiology (ESC) guidelines differentiate bleeding into:

- mild (usually BARC 2);
- severe, non-life-threatening (BARC 3a);
- life-threatening or critical organ bleeding (BARC 3b).

General recommendations for bleeding during NOAC treatment include assessment of baseline hemostatic parameters (hemoglobin, hematocrit, platelet count, PT, TT, APTT) and renal function. As mentioned earlier, the effect of FXa inhibitors should not be assessed and the time of the last dose should not be estimated on the basis of coagulation parameter results. It should be kept in mind that such parameters can be abnormal for several

other reasons, especially in cases of massive bleeding or intravascular coagulation syndrome. Only normal anti-Xa activity, evaluated using methods with adequate sensitivity, excludes therapeutic levels of Xa inhibitors.

The following are the recommendations for bleeding management according to its severity:

- Mild bleeding:
 - delay or skip the next NOAC dose;
 - the dose and type of NOAC used should be carefully reviewed before restarting treatment, and the need for other medications that increase the risk of bleeding should be verified.
- Severe, non-life-threatening bleeding:
 - it is important to stop bleeding and maintain adequate vascular volume: mechanical surgical or endoscopic compression to achieve hemostasis, fluid therapy, transfusion of red blood cell concentrate when Hb is reduced to under < 7 – 8 g/dl, transfusion of platelet cell concentrate if the platelet count is ≤ 50 G/l or patient has been taking antiplatelet drugs, administration of tranexamic acid, causal treatment of bleeding;
 - the timing of the last NOAC dose should be determined;
 - activated charcoal may be considered within 3–4 hours of taking the NOAC;
 - in patients treated with dabigatran, consider idarucizumab or hemodialysis.

Life-threatening bleeding or bleeding into a critical organ

In patients treated with NOACs who experience such bleeding, in addition to implementing standard bleeding management (as above), it is advisable to reverse the anticoagulant effect. According to the recommendations of




Figure 3. Reversal of non-vitamin K antagonist oral anticoagulant action. Based on: Tomaselli GF, Mahaffey KW, Cuker A, et al. 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: A report of the American College of Cardiology Task Force on expert consensus decision pathways. *J Am Coll Cardiol.* 2017; 70: 3042–3067

Abbreviations: aPCC, activated prothrombin complex concentrates; i.v., intravenous; PCC, prothrombin complex concentrates

the European and American clinical societies, the first-line management should be idarucizumab 5 g i.v. for patients treated with dabigatran, or AA for patients treated with apixaban and rivaroxaban (dosage above).

PCC or aPCC, on the other hand, are recommended as NOAC reversal drugs in the absence of an available antidote. PCC is used at a dose of 25 IU/kg body weight, and the dose can be repeated 1–2 times, if necessary, up to a dose of 50–75 IU/kg body weight. aPCC is used at a dose of 50 IU/kg body weight, up to a maximum of 200 IU/kg body weight.

Although the reversal of NOAC anticoagulant effect is sometimes insufficient by itself to stop bleeding, it may allow for other needed invasive interventions.

Neither vitamin K nor protamine sulfate is effective in treating bleeding in NOAC-treated patients. Similarly, FFP is not applicable to control bleeding in such patients. This is mainly due to the NOACs present in the plasma, which inhibit the activity of clotting factors after FFP administration. Hence, a transfusion of a large volume of FFP would be needed to achieve a clinically relevant effect [1, 51].

Figure 3 presents the American College of Cardiology recommendations for the management of bleeding in patients treated with NOACs [53].

Andexanet alfa vs. PCC (current therapeutic standard)

Based on the ESC guidelines, PCC or aPCC are recommended as NOAC reversal drugs for life-threatening bleeding in the absence of an available antidote, and the choice between the two agents should depend on the availability and experience of individual centers [1].

For major bleeding, AA has more evidence of effective and safe anticoagulant reversal than PCC. Several cohort

studies on bleeding patients treated with anti-Xa agents who received PCC have been published, with somewhat conflicting results [54–57]. While Schulman and Majeed reported similar efficacy of PCC and AA, the study group sizes were quite small (66 and 84 patients, respectively). AA, on the other hand, underwent an extensive preclinical program on animal models followed by cohorts of non-bleeding patients treated with various anti-FXa agents [58, 59]. Its effectiveness was finally confirmed in the ANNEXA-4 trial, which recruited patients with severe bleeding (intracranial or gastrointestinal) treated with various anti-Xa agents [2].

Studies comparing the Food and Drug Administration approved AA and off-label PCC. A study by Costa et al. [36], argues in favor of AA due to its greater potential to achieve hemostasis. Schmidt et al. [59], on the other hand, documented similar efficacy of both agents, with a higher incidence of thrombotic events after AA. Evaluation of both products head-to-head is attempted in the ongoing ANNEXA-I trial (NCT03661528), comparing the use of AA with “usual care” in patients with intracranial hemorrhage taking FXa antagonists, with usual care in many situations consisting of PCC. However, the trial began in early 2019 and is still ongoing.

Resumption of anticoagulant treatment

It is unclear at what time after AA administration factor Xa inhibitors or heparin can be re-administered. The effect of AA ceases about 2 hours after drug infusion is stopped, at which time the reappearance of low concentrations of rivaroxaban and apixaban in the bloodstream can be observed.

Returning to anticoagulant therapy after a history of severe bleeding is associated with a better prognosis, a reduction in the risk of death and thromboembolic com-

Table 6. The amount of time that should pass from the last dose of non-vitamin K antagonist oral anticoagulants (NOACs) before planned surgical procedures

Bleeding risk	Apixaban/rivaroxaban		Dabigatran	
	Low	High	Low	High
CrCl ≥80 ml/min	≥24 h	≥48 h	≥24 h	≥48 h
CrCl 50–79 ml/min			≥36 h	≥72 h
CrCl 30–49 ml/min			≥48 h	≥96 h
CrCl 15–29 ml/min	≥36 h		Contradicted in the MPI	
CrCl < 15 ml/min	Contradicted in the MPI			

For procedures with a very low risk of bleeding, the procedure should be performed during the period of minimum plasma concentrations of NOACs (12 or 24 hours after the last dose for twice-daily or once-daily administration, respectively)

Based on [1].

Abbreviations: CrCl, creatinine clearance; MPI, Medication Package Insert

plications, but also with increased risk of bleeding [60]. In contrast, the risk of bleeding, especially hematoma expansion in the HS, is highest within the first 72 hours. Hence, the timing of NOAC reintroduction is a crucial but currently unclear issue. Current retrospective studies, expert opinions, and clinical practice regarding the timing of resumption of anticoagulant treatment vary widely. The ESC guidelines recommend resuming NOAC treatment after 4–8 weeks following intracranial bleeding, after considering the benefits and risks and taking imaging results into account. For gastrointestinal bleeding, NOACs should be started as soon as clinically feasible [1, 2, 60].

Factors associated with increased risk of recurrent gastrointestinal bleeding:

- no identified source of bleeding and no reversible cause;
- bleeding during a break in NOAC use/while on non-therapeutic doses of NOACs;
- multiple angiodysplasia-like lesions in the gastrointestinal tract;
- chronic alcohol abuse;
- old age.

Factors associated with increased risk of recurrent CNS bleeding:

- lack of reversible cause;
- bleeding during interruption of NOAC use/during use of non-therapeutic doses of NOACs;
- concomitant antiplatelet treatment;
- modifiable risk factors:
 - uncontrolled hypertension,
 - alcohol/nicotine/sympathomimetic drug dependence,
 - low low-density lipoprotein/triglycerides,
 - concomitant antiplatelet treatment;
- non-modifiable:
 - older age,
 - Asian race,
 - male sex,
 - renal failure,
 - small vessel disease,
 - cerebral amyloid angiopathy,
 - microbleed presence in brain imaging.

Currently, there are no randomized trials on the timing of NOAC resumption after bleeding. Four phase III trials on resumption of anticoagulant treatment after intracranial bleeding are ongoing (ENRICH AF, ASPIRE, PRESTIGE-AF, and Restart TICrH) [2].

At present, the decision to resume anticoagulant treatment should be based on the patient's clinical condition, his/her thromboembolic risk, and whether the bleeding site has been identified and treatment to stop the bleeding has been successfully implemented.

In the case of bleeding resulting from reversible causes or post-traumatic bleeding, anticoagulant treatment can usually be initiated after the cause has been identified and eliminated. There are aspects of both gastrointestinal bleeding and intracranial hemorrhages that support the reintroduction of anticoagulant treatment or its discontinuation.

For major bleeding without an identified, reversible cause, the decision on anticoagulant treatment should depend on the possible net benefit of treatment and assessment of the risk of recurrent bleeding. Another option, in the case of contraindications to anticoagulant therapy in atrial fibrillation, is percutaneous closure of the left atrial appendage (recommendation grade IIb). However, even in this case, the patient requires continuation of antiplatelet therapy [1].

PATIENTS BEFORE SURGICAL PROCEDURES

Only non-cardiac surgical procedures performed on an elective and expedited basis require that discontinuation of anticoagulants at an appropriate time. NOACs, with normal creatinine clearance, should be discontinued more than 24 hours before low-risk surgery and 48 hours before high-risk surgery (e.g., procedures on the aorta, visceral and iliac arteries). The longest withdrawal, over 72 and 96 hours, is required for dabigatran in patients with impaired renal function (Table 6).

The exact timing of discontinuation should depend primarily on the type of treatment and the patient's renal function. In contrast, there is no evidence that the timing of withdrawal of NOACs before surgery depends on their residual plasma concentrations. In addition, the concentra-




Figure 4. Proposed regimen for patients treated with NOACs before NCS (based on: [61])

Abbreviations: eGFR, estimated glomerular filtration rate; NCS, non-cardiac surgery; NOAC, non-vitamin K antagonist oral anticoagulants; other — see Table 1

tions of NOACs that allow safe performance of particular surgical procedures are not known [61].

The situation is different for procedures with immediate and urgent indications. In these cases, according to the ESC recommendations, it is recommended that NOACs be discontinued immediately, and a full blood clotting panel (PT, aPTT, anti-Xa, etc.) and plasma NOAC determination, if available, should be performed. Surgery or intervention, if possible, should be delayed for at least 12 hours, and optimally for 24 hours after the last NOAC dose. If the patient requires immediate life-saving surgery associated with intermediate or high risk of bleeding, and the last dose of anticoagulant was taken earlier, it is advisable to use reversal agents (Figure 4) [1, 61].

Studies on NOAC reversal in urgent surgery situations, part of the process to register AA and idarucizumab, are difficult to compare.

A phase IIIb to IV study (ANNEXA-4) evaluated the efficacy and safety of AA in patients with acute major bleeding treated with FXa inhibitors but did not include patients receiving anticoagulant therapy, requiring surgery, or emergency invasive procedures [2]. In addition, the

exclusion criteria for ANNEXA-4 included planned surgery within 12 hours. Nevertheless, off-label administration of AA is allowed in exceptional situations when there is a need for immediate life-saving surgical intervention in patients treated with a FXa inhibitor. The effectiveness of such a post-treatment strategy has been confirmed repeatedly in clinical cases and retrospective studies [15, 16, 62]. Unfortunately, because of AA's ability to non-specifically bind all factor Xa inhibitors, the treatment is problematic for interventions requiring the administration of UFH or LMWH [20]. The AA treatment should not be monitored based on anti-Xa activity. Commercially available anti-Xa activity assays are inadequate for its measurement after AA administration, as the resulting anti-Xa activity assay results are overestimated, leading to a significant underestimation of the change in AA activity [63]. If NOAC reversal agents are unavailable, PCC or aPCC should be considered despite lack of clear evidence of their safety and efficacy in this indication (Table 5). An additional option is the use of recombinant activated factor VII [1].

The composition of PCC includes clotting factors: II, VII, IX, and X, with less protein C and protein S, and a small

amount of heparin. In aPCC, on the other hand, there are both activated and non-activated factors II, VII, IX, and X. PCC preparations supplied by different manufacturers vary slightly in the amount of clotting factors and their inhibitors.

To minimize the risk of supratentorial hematoma, it is also advised to preferentially choose general anesthesia, not spinal anesthesia, in cases requiring urgent or immediate surgery.

In vascular surgery departments, immediate and urgent procedures are primarily performed to treat:

- ruptured aneurysms of the abdominal aorta, thoracoabdominal aorta, iliac arteries, or visceral arteries;
- traumas in which large vessels were damaged, including those responsible for limb vitality;
- acute ischemia of the upper or lower extremities.

Ruptured aneurysm surgery carries a very high risk of hemorrhagic complications. This is influenced by the condition of the patient admitted with such a diagnosis — most often with symptoms of hemorrhagic shock and coagulation disorders already present. Classic surgery with opening of the peritoneal cavity and retroperitoneal space, with active anticoagulants, is fraught with a major risk of uncontrollable bleeding and, thus, a substantial risk of death. Nowadays, it is possible to perform surgery for ruptured aortic aneurysms using an endovascular approach, which can potentially reduce the risk of hemorrhagic complications. However, this should not change the surgical approach in this group of patients, as conversion from endovascular to conventional surgery may be necessary during the procedure. Large vessel injuries in the abdominal or thoracic cavity, absolutely require the use of FXa inhibitor reversal drugs. This is primarily related to the extent of the surgery and the need to supply the injured vessels.

Surgeries for acute ischemia of the upper and lower extremities are very common procedures within the remit of the vascular Emergency Department. Even though these procedures are much less burdensome for the patient, usually with little vascular access and skin incision, NOAC inhibition should also be considered in such cases. Some of these procedures can be performed percutaneously, in the form of mechanical thrombectomy. In cases of both open and endovascular procedures, there is a risk of iatrogenic perforation of the vessel, and, consequently, uncontrolled bleeding. In cases of acute, long-lasting ischemia of the limb, compartment syndrome may occur. This symptom should absolutely be treated surgically by performing a fasciotomy, usually in a three-compartment open approach. This procedure involves decompressing the swollen and, with high probability, necrotic muscle groups of the ischemic limb by cutting through the fascia and skin, which involves the risk of major bleeding.

Although there have been no publications on fibrinolytic treatment in patients treated with NOACs, it seems that thrombolytic treatment of acute limb ischemia should be contraindicated in this group of patients.

The current position on open and endovascular procedures with vascular access is that preventing complete control of bleeding (e.g., femoral access) for immediate and urgent vascular surgery requires the use of NOAC reversal in all cases.

Unfortunately, the effect of AA persists only for about 2 hours after the end of the infusion, which is a significant problem for patients undergoing surgical procedures that last several hours. In such cases, inhibition of anti-Xa activity by AA may not be sufficient to maintain hemostasis [17].

Given the above, in the absence of life-threatening bleeding, AA administration should be delayed until immediately before surgery to ensure maximum anticoagulant reversal and avoid repeated doses. However, there are examples in the literature of double administration of a standard dose of AA [64] or a single standard dose of AA with prolonged infusion of the drug at a half-reduced rate during prolonged surgery [65].

Hence, it remains necessary to create multidisciplinary guidelines for determining the risk of perioperative bleeding, as well as the timing of AA administration for specific procedures. As new data emerge, we expect that the use of AA in the perioperative setting will evolve.

THE IMPORTANCE OF COORDINATING INTERDISCIPLINARY COLLABORATION IN DECISIONS TO USE ANDEXANET ALFA

The decision to reverse the action of a NOAC and administer an antidote in the form of an AA is difficult and requires assessment of the possible benefits and risks. Such a decision can only be made through interdisciplinary cooperation of specialists from different fields. Depending on the type of side effects of NOAC use, the decision-making process will include neurologists, surgeons, or emergency medicine physicians. However, cardiologists definitely have the most experience in the use of NOACs because these drugs are mostly administered for cardiac indications. It would, therefore, be advisable for cardiologists to coordinate these multispecialty teams and for AA to be located in cardiology departments.

DETERMINATION OF ANDEXANET ALFA FINANCING CONDITIONS

Currently, the only substance registered in Europe and the United States for the specific reversal of the anticoagulant effect of apixaban and rivaroxaban is AA (ATC code: V03AB38 — all other drugs, antidotes). The US Food and Drug Administration registered the drug as a breakthrough designation in November 2013. In May 2018, the drug received accelerated approval [66, 67]. In Europe, including Poland, the European Medicine Agency, in April 2019, granted AA conditional approval, which is used for drugs of particular public health importance and to address population health needs when the clinical benefits outweigh the risks of their use [17].

Table 7. Recommendations for the use of andexanet alfa in patients with life-threatening or unmanageable hemorrhages

Anticoagulation Forum 2018	Suggested	[68]
American Society of Hematology 2018	Suggested	[69]
European Stroke Organisation 2019	Recommended in the first-line treatment	[70]
American College of Cardiology 2020	Recommended in the first-line treatment	[71]
Japanese Circulation Society/Japanese Heart Rhythm Society 2022	For consideration	[72]
American College of Emergency Physicians 2020	Recommended	[73]
American Heart Association/American College of Cardiology/Heart Rhythm Society 2019	Potentially useful	[74]
Asia Pacific Heart Rhythm Society 2021	Potentially useful	[75]
European Heart Rhythm Association 2021	Recommended	[76]
Deutsche Gesellschaft für Neurologie 2022	For consideration	[77]
American College of Chest Physicians 2018	Recommended	[78]
Spanish Society of Digestive Pathology/Spanish Society of Thrombosis and Haemostasis 2022	Recommended, if available	[79]

Thus, AA is currently recommended for reversal of rivaroxaban and apixaban in patients with life-threatening or unmanageable hemorrhages, i.e. for use in emergency and life-threatening conditions in the hospital setting, and in Poland, there is currently no dedicated public funding for this drug in the hospital lump sum system (Table 7). Thus, there is an urgent need to create a billing product for this drug, e.g. by including it in the aggregated product catalog allowing it to be included with other procedures performed within the existing diagnosis-related groups dedicated to the treatment of hemorrhage, or the catalog of separate products: 5.52.01.0001384 — hospitalization for reasons not covered elsewhere. Before this can happen, however, there is an urgent need for hospitals to seek alternative methods of financing for individual patients.

CONCLUSIONS

Andexanet alfa is recommended for patients with life-threatening and unmanageable hemorrhages (major bleeding according to the ISTH or BARC 3b), including HS and post-traumatic bleeding, in patients using FXa inhibitors. Prothrombin complex factor concentrate or aPCC, on the other hand, are recommended as reversal agents for all NOACs in the absence of an available antidote.

Management of patients with severe bleeding includes determining the type and dose of NOAC used and the time that elapsed from its last administration. A full panel of clotting parameters should be performed, including plasma NOAC concentrations, if the test is available. The ISTH suggests considering NOAC reversal in patients with severe bleeding and NOAC levels >50 ng/ml. Currently, it is believed that drug-specific chromogenic anti-Xa assays are most appropriate for estimating rivaroxaban and apixaban plasma levels. The absence of anti-Xa activity determined using these assays excludes clinically relevant plasma NOAC levels.

In contrast, the AA dose should not be modified based on the results of hemostasis tests. Rather, it should depend solely on the time that elapsed from the last dose of the FXa inhibitor and the long-term dosage of the anticoagulant. When using rivaroxaban >10 mg, apixaban >5 mg, or when the dose is unknown, it is recommended to administer a high dose of AA when the drugs were taken

within 7 hours, or a low dose when a minimum of 8 hours has passed. When using rivaroxaban \leq 10 mg and apixaban \leq 5 mg, a low dose of AA is recommended. When the time of the last NOAC dose is unknown, a high dose should be administered to long-term users of higher doses of NOACs, and a low dose for long-term users of lower doses.

AA is administered as an i.v. bolus of 400 mg (low dose) or 800 mg (high dose) at a rate of 30 mg/min. An i.v. infusion of the drug is then introduced, at a rate of 4 mg/min (low dose) or 8 mg/min (high dose) for 120 minutes. Maximum reversal of anti-Xa activity occurs within two minutes of the end of the bolus, and continued continuous i.v. infusion allows the effect to be maintained for 2 hours afterward.

Measuring anti-Xa has no use in monitoring FXa anti-coagulant effect reversal. Treatment monitoring should be based mainly on clinical parameters — evaluation of hemostasis or side effects, including thromboembolic events.

Due to the high and multifactorial thromboembolic risk in patients requiring AA administration, resumption of anticoagulant treatment should be considered as early as possible after bleeding is contained.

Based on the available literature, it is also known that the use of AA can be considered off-label in life-threatening clinical situations requiring urgent surgical intervention. Surgery or intervention, if possible, should be delayed for at least 12 hours, and optimally for 24 hours, after the last NOAC dose. When a patient requires immediate life-saving surgery associated with intermediate or high risk of bleeding, and the last dose of anticoagulant has already been taken, antidote administration is indicated. Unfortunately, the short duration of AA action after the end of the infusion poses a significant problem for patients undergoing surgical procedures lasting many hours. Formulating definitive recommendations on the use of AA for this indication requires further research. The ISTH suggests the need to reverse FXa inhibitors before surgery in patients with high risk of bleeding and NOAC levels >30 ng/ml.

Unfortunately, in Poland, there is no dedicated public funding for AA in the hospital lump sum funding system. Thus, there is an urgent need to create a billing product for this drug and to seek alternative methods for financing for individual patients within hospital procedures.

Article information

Conflict of interest: None declared.

Funding: None.

Open access: This article is available in open access under Creative Commons Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, which allows downloading and sharing articles with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially. For commercial use, please contact the journal office at kardiologiapolska@ptkardio.pl.

REFERENCES

- Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. *Europace*. 2021; 23(10): 1612–1676, doi: [10.1093/europace/euab065](https://doi.org/10.1093/europace/euab065), indexed in Pubmed: 33895845.
- Milling TJ Jr, Middeldorp S, Xu L, et al. Final study report of andexana for major bleeding with factor Xa inhibitors. *Circulation*. 2023; 147(13): 1026–1038, doi: [10.1161/CIRCULATIONAHA.121.057844](https://doi.org/10.1161/CIRCULATIONAHA.121.057844), indexed in Pubmed: 36802876.
- Mutscher E, Geisslinger G, Kroeme HK, Menzel S, Ruth P. *Farmakologia i toksykologia*. Wyd. IV. MedPharm Polska, Wrocław 2013.
- Douxflis J, Adcock DM, Bates SM, et al. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. *Thromb Haemost*. 2018; 118(3): 437–450, doi: [10.1055/s-0038-1627480](https://doi.org/10.1055/s-0038-1627480), indexed in Pubmed: 29433148.
- Gorczyca-Głowacka I, Kapłon-Cieślicka A, Welnicki M, et al. Rules for using reduced doses of non-vitamin K antagonist oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation. The expert opinion of the Working Group on Cardiovascular Pharmacotherapy of the Polish Cardiac Society. *Kardiol Pol*. 2022; 80(12): 1299–1306, doi: [10.33963/KP.a2022.0286](https://doi.org/10.33963/KP.a2022.0286), indexed in Pubmed: 36601886.
- Douxflis J, Adcock DM, Bates SM, et al. 2021 update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct oral anticoagulants. *Thromb Haemost*. 2021; 121(8): 1008–1020, doi: [10.1055/a-1450-8178](https://doi.org/10.1055/a-1450-8178), indexed in Pubmed: 33742436.
- Levy JH, Ageno W, Chan NC, et al. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. *J Thromb Haemost*. 2016; 14(3): 623–627, doi: [10.1111/jth.13227](https://doi.org/10.1111/jth.13227), indexed in Pubmed: 26911798.
- Akpan JJ, Cuker A. Laboratory assessment of the direct oral anticoagulants: who can benefit? *Kardiol Pol*. 2021; 79(6): 622–630, doi: [10.33963/KP.a2021.0021](https://doi.org/10.33963/KP.a2021.0021), indexed in Pubmed: 34029374.
- Hutt Centeno E, Militello M, Gomes MP. Anti-Xa assays: What is their role today in antithrombotic therapy? *Cleve Clin J Med*. 2019; 86(6): 417–425, doi: [10.3949/ccjm.86a.18029](https://doi.org/10.3949/ccjm.86a.18029), indexed in Pubmed: 31204981.
- Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. *Nat Med*. 2013; 19(4): 446–451, doi: [10.1038/nm.3102](https://doi.org/10.1038/nm.3102), indexed in Pubmed: 23455714.
- Pine PR, Hollenbach SJ, Tan S, et al. Andexanet alfa reverses edoxaban-induced anticoagulation in a rabbit liver laceration model of acute bleeding. Presented at the European Society of Cardiology Congress. London, United Kingdom, 29 August–2 September 2015.
- Lu G, Conley PB, Leeds JM, et al. A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers. *Blood Adv*. 2020; 4(4): 728–739, doi: [10.1182/bloodadvances.2019000885](https://doi.org/10.1182/bloodadvances.2019000885), indexed in Pubmed: 32092140.
- Siegal D, Lu G, Leeds JM, et al. Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa. *Blood Adv*. 2017; 1(21): 1827–1838, doi: [10.1182/bloodadvances.2017007112](https://doi.org/10.1182/bloodadvances.2017007112), indexed in Pubmed: 29296829.
- Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. *N Engl J Med*. 2015; 373(25): 2413–2424, doi: [10.1056/NEJMoa1510991](https://doi.org/10.1056/NEJMoa1510991), indexed in Pubmed: 26559317.
- Bradshaw PG, Keegan SP, Droegge ME, et al. Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures. *Pharmacotherapy*. 2022; 42(10): 780–791, doi: [10.1002/phar.2727](https://doi.org/10.1002/phar.2727), indexed in Pubmed: 36073083.
- Brown CS, Scott RA, Sridharan M, et al. Real-world utilization of andexanet alfa. *Am J Emerg Med*. 2020; 38(4): 810–814, doi: [10.1016/j.ajem.2019.12.008](https://doi.org/10.1016/j.ajem.2019.12.008), indexed in Pubmed: 31870672.
- European Medicines Agency AaSoPC. https://www.ema.europa.eu/en/documents/product-information/ondexxya-epar-product-information_en.pdf (accessed: September 12, 2020).
- Liu J, Elsamadisi P, Phillips E, et al. Four-factor prothrombin complex concentrate plus andexanet alfa for reversal of factor Xa inhibitor-associated bleeding: Case series. *Am J Health Syst Pharm*. 2022; 79(16): 1323–1329, doi: [10.1093/ajhp/zxac079](https://doi.org/10.1093/ajhp/zxac079), indexed in Pubmed: 35291008.
- Bradshaw PG, Keegan S, Foertsch M, et al. Andexanet alfa after 4-factor PCC administration for intracranial hemorrhage: a case series. *J Thromb Thrombolysis*. 2022; 54(2): 295–300, doi: [10.1007/s11239-022-02658-w](https://doi.org/10.1007/s11239-022-02658-w), indexed in Pubmed: 35507109.
- Watson CJ, Zettervall SL, Hall MM, et al. Difficult Intraoperative Heparinization Following Andexanet Alfa Administration. *Clin Pract Cases Emerg Med*. 2019; 3(4): 390–394, doi: [10.5811/cpcem.2019.9.43650](https://doi.org/10.5811/cpcem.2019.9.43650), indexed in Pubmed: 31763596.
- Eche IM, Elsamadisi P, Wex N, et al. Intraoperative unfractionated heparin unresponsiveness during endovascular repair of a ruptured abdominal aortic aneurysm following administration of andexanet alfa for the reversal of rivaroxaban. *Pharmacotherapy*. 2019; 39(8): 861–865, doi: [10.1002/phar.2306](https://doi.org/10.1002/phar.2306), indexed in Pubmed: 31251821.
- Greenberg SM, Ziai WC, Cordonnier C, et al. 2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association/American Stroke Association. *Stroke*. 2022; 53(7): e282–e361, doi: [10.1161/STR.0000000000000407](https://doi.org/10.1161/STR.0000000000000407), indexed in Pubmed: 35579034.
- Jolink WMT, Klijn CJM, Brouwers PJ, et al. Time trends in incidence, case fatality, and mortality of intracerebral hemorrhage. *Neurology*. 2015; 85(15): 1318–1324, doi: [10.1212/WNL.0000000000002015](https://doi.org/10.1212/WNL.0000000000002015), indexed in Pubmed: 26377254.
- Flaherty ML, Kissela B, Woo D, et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. *Neurology*. 2007; 68(2): 116–121, doi: [10.1212/01.wnl.0000250340.05202.8b](https://doi.org/10.1212/01.wnl.0000250340.05202.8b), indexed in Pubmed: 17210891.
- Hankey GJ. Intracranial hemorrhage and novel anticoagulants for atrial fibrillation: what have we learned? *Curr Cardiol Rep*. 2014; 16(5): 480, doi: [10.1007/s11886-014-0480-9](https://doi.org/10.1007/s11886-014-0480-9), indexed in Pubmed: 24643903.
- Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med*. 2011; 365(10): 883–891, doi: [10.1056/NEJMoa1009638](https://doi.org/10.1056/NEJMoa1009638), indexed in Pubmed: 21830957.
- Granger CB, Alexander JH, McMurray JJV, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2011; 365(11): 981–992, doi: [10.1056/NEJMoa1107039](https://doi.org/10.1056/NEJMoa1107039), indexed in Pubmed: 21870978.
- Wu T, Lv C, Wu L, et al. Risk of intracranial hemorrhage with direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. *J Neurol*. 2022; 269(2): 664–675, doi: [10.1007/s00415-021-10448-2](https://doi.org/10.1007/s00415-021-10448-2), indexed in Pubmed: 33594452.
- Flaherty ML, Haverbusch M, Sekar P, et al. Location and outcome of anticoagulant-associated intracerebral hemorrhage. *Neurocrit Care*. 2006; 5(3): 197–201, doi: [10.1385/NCC:5:3:197](https://doi.org/10.1385/NCC:5:3:197), indexed in Pubmed: 17290088.
- Troyer C, Nguyen W, Xie A, et al. Retrospective review of andexanet alfa versus 4-factor prothrombin complex concentrate for reversal of doac-associated intracranial hemorrhage. *J Thromb Thrombolysis*. 2023; 55(1): 149–155, doi: [10.1007/s11239-022-02715-4](https://doi.org/10.1007/s11239-022-02715-4), indexed in Pubmed: 36355324.
- Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. *JAMA*. 2015; 313(8): 824–836, doi: [10.1001/jama.2015.0846](https://doi.org/10.1001/jama.2015.0846), indexed in Pubmed: 25710659.
- Demchuk AM, Yue P, Zotova E, et al. Hemostatic efficacy and anti-FXa (factor Xa) reversal with andexanet alfa in intracranial hemorrhage: AN-NEXA-4 substudy. *Stroke*. 2021; 52(6): 2096–2105, doi: [10.1161/STROKEAHA.120.030565](https://doi.org/10.1161/STROKEAHA.120.030565), indexed in Pubmed: 33966491.

33. Barra ME, Das AS, Hayes BD, et al. Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages. *J Thromb Haemost.* 2020; 18(7): 1637–1647, doi: 10.1111/jth.14838, indexed in Pubmed: 32291874.
34. Vestal ML, Hodulik K, Mando-Vandrick J, et al. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage. *J Thromb Thrombolysis.* 2022; 53(1): 167–175, doi: 10.1007/s11239-021-02495-3, indexed in Pubmed: 34101050.
35. Giovino A, Shomo E, Busey KV, et al. An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage. *Clin Neurol Neurosurg.* 2020; 195: 106070, doi: 10.1016/j.clineuro.2020.106070, indexed in Pubmed: 32679541.
36. Costa OS, Connolly SJ, Sharma M, et al. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis. *Crit Care.* 2022; 26(1): 180, doi: 10.1186/s13054-022-04043-8, indexed in Pubmed: 35710578.
37. Ammar AA, Ammar MA, Owusu KA, et al. Andexanet alfa versus 4-factor prothrombin complex concentrate for reversal of factor Xa inhibitors in intracranial hemorrhage. *Neurocrit Care.* 2021; 35(1): 255–261, doi: 10.1007/s12028-020-01161-5, indexed in Pubmed: 33403588.
38. Pham H, Medford WG, Horst S, et al. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages. *Am J Emerg Med.* 2022; 55: 38–44, doi: 10.1016/j.ajem.2022.02.029, indexed in Pubmed: 35272069.
39. Parsels KA, Seabury RW, Zyck S, et al. Andexanet alfa effectiveness and safety versus four-factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage while on apixaban or rivaroxaban: A single-center, retrospective, matched cohort analysis. *Am J Emerg Med.* 2022; 55: 16–19, doi: 10.1016/j.ajem.2022.02.036, indexed in Pubmed: 35245776.
40. Lipski M, Pasciolla S, Wojcik K, et al. Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage. *J Thromb Thrombolysis.* 2023; 55(3): 519–526, doi: 10.1007/s11239-022-02752-z, indexed in Pubmed: 36566473.
41. Chaudhary R, Singh A, Chaudhary R, et al. Evaluation of direct oral anticoagulant reversal agents in intracranial hemorrhage. *JAMA Network Open.* 2022; 5(11): e2240145, doi: 10.1001/jamanetworkopen.2022.40145, indexed in Pubmed: 36331504.
42. Nederpelt CJ, Naar L, Krijnen P, et al. Andexanet alfa or prothrombin complex concentrate for factor xa inhibitor reversal in acute major bleeding: a systematic review and meta-analysis. *Crit Care Med.* 2021; 49(10): e1025–e1036, doi: 10.1097/CCM.0000000000005059, indexed in Pubmed: 33967205.
43. Alexion Pharmaceuticals: Trial of andexanet in ICH patients receiving an oral FXa inhibitor. *ClinicalTrials.gov* Identifier NCT03661528. September 9, 2022. <https://clinicaltrials.gov/ct2/show/NCT03661528> (October 9, 2022).
44. Veitch AM, Radaelli F, Alikhan R, et al. Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update. *Gut.* 2021; 70(9): 1611–1628, doi: 10.1136/gutjnl-2021-325184, indexed in Pubmed: 34362780.
45. Gralnek IM, Stanley AJ, Morris AJ, et al. Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) Guideline — update 2021. *Endoscopy.* 2021; 53(3): 300–332, doi: 10.1055/a-1369-5274, indexed in Pubmed: 33567467.
46. Connolly SJ, Milling TJ Jr, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. *N Engl J Med.* 2016; 375(12): 1131–1141, doi: 10.1056/nejmoa1607887, indexed in Pubmed: 27573206.
47. Gralnek IM, Camus Duboc M, Garcia-Pagan JC, et al. Endoscopic diagnosis and management of esophagogastric variceal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. *Endoscopy.* 2022; 54(11): 1094–1120, doi: 10.1055/a-1939-4887, indexed in Pubmed: 36174643.
48. Triantafyllou K, Gkolfakis P, Gralnek IM, et al. Diagnosis and management of acute lower gastrointestinal bleeding: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. *Endoscopy.* 2021; 53(8): 850–868, doi: 10.1055/a-1496-8969, indexed in Pubmed: 34062566.
49. Abraham NS, Barkun AN, Sauer BG, et al. American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: management of anticoagulants and antiplatelets during acute gastrointestinal bleeding and the periendoscopic period. *Am J Gastroenterol.* 2022; 117(4): 542–558, doi: 10.14309/ajg.0000000000001627, indexed in Pubmed: 35297395.
50. Rozporządzenie Ministra Zdrowia z dnia 10 maja 2002 r. w sprawie szpitalnego oddziału ratunkowego. <https://www.prawo.pl/akty/dz-u-2002-74-687,16964620.html> (accessed: June 27, 2023).
51. Kuliczowski W, Gierlotka M, Tycińska A, et al. Management of bleeding in patients hospitalized in the cardiac intensive care unit. Expert opinion of the Association of Intensive Cardiac Care and Section of Cardiovascular Pharmacotherapy of the Polish Cardiac Society in cooperation with specialists in other fields of medicine [article in Polish]. *Kardiologia Pol Educational Issues.* 2020; 78(1): 88–115.
52. Undas A, Drabik L, Potpara T. Bleeding in anticoagulated patients with atrial fibrillation: practical consideration. *Kardiologia Pol Educational Issues.* 2020; 78(3): 136–152.
53. Tomasselli GF, Mahaffey KW, Cuker A, et al. 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on expert consensus decision pathways. *J Am Coll Cardiol.* 2017; 70(24): 3042–3067, doi: 10.1016/j.jacc.2017.09.1085, indexed in Pubmed: 29203195.
54. Majeed A, Ågren A, Holmström M, et al. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. *Blood.* 2017; 130(15): 1706–1712, doi: 10.1182/blood-2017-05-782060, indexed in Pubmed: 28835439.
55. Schulman S, Gross PL, Ritchie B, et al. Prothrombin complex concentrate for major bleeding on factor Xa inhibitors: a prospective cohort study. *Thromb Haemost.* 2018; 118: 842–51, doi: 10.1055/s-0038-1636541, indexed in Pubmed: 29564837.
56. Gerner ST, Kuramatsu JB, Sembill JA, et al. Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage. *Ann Neurol.* 2018; 83(1): 186–196, doi: 10.1002/ana.25134, indexed in Pubmed: 29314216.
57. Arachchillage DRJ, Alavian S, Griffin J, et al. Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding. *Br J Haematol.* 2019; 184(5): 808–816, doi: 10.1111/bjh.15705, indexed in Pubmed: 30515764.
58. Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. *Nat Med.* 2013; 19(4): 446–451, doi: 10.1038/nm.3102, indexed in Pubmed: 23455714.
59. Schmidt LE, Hinton MS, Martin ND. Real-world reversal of factor xa inhibition in the setting of major life-threatening bleeding or urgent surgery. *J Pharm Pract.* 2022; 8971900221125516, doi: 10.1177/08971900221125516, indexed in Pubmed: 36083782.
60. Milling TJ, King B, Yue P, et al. ANNEXA-4 Investigators. Restart of anticoagulant therapy and risk of thrombosis, rebleeding, and death after factor Xa inhibitor reversal in major bleeding patients. *Thromb Haemost.* 2021; 121(8): 1097–1106, doi: 10.1055/a-1400-6159, indexed in Pubmed: 33634446.
61. Halvorsen S, Mehilli J, Cassese S, et al. et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. *Eur Heart J.* 2022; 43(39): 3826–3924, doi: 10.1093/eurheartj/ehac270, indexed in Pubmed: 36017553.
62. Kainz M, Bsuehner P, Schellongowski P, et al. Intraoperative off-label reversal of apixaban by andexanet alfa while on VA-ECMO immediately after emergent surgery for acute type a aortic dissection. *J Cardiothorac Vasc Anesth.* 2021; 35(1): 262–264, doi: 10.1053/j.jvca.2020.08.017, indexed in Pubmed: 32868154.
63. Portola Netherlands, B.V. in Agreement with the European Medicines Agency and the National Competent Authority. Ondexxya (Andexanet

- Alfa): Commercial Anti-FXa activity assays are unsuitable for measuring Anti-FXa activity following administration of andexanet alfa. *Communication to Healthcare Professional* 2020.
64. Flaherty D, Connors JM, Singh S, et al. Andexanet alfa for urgent reversal of apixaban before aortic surgery requiring cardiopulmonary bypass: a case report. *A A Pract.* 2019; 13(7): 271–273, doi: [10.1213/XAA.0000000000001052](https://doi.org/10.1213/XAA.0000000000001052), indexed in Pubmed: 31265446.
 65. Philpott CD, Ernst NE, Makley AT, et al. Case report: extended duration andexanet alfa infusion in a surgical trauma patient. *J Pharm Pract.* 2022; 36(4): 1002–1007, doi: [10.1177/08971900221078779](https://doi.org/10.1177/08971900221078779).
 66. Portola gets FDA breakthrough therapy status for andexanet alfa. 2013. <https://www.pharmaceutical-technology.com/uncategorized/newsportola-gets-fda-breakthrough-therapy-status-for-andexanet-alfa/> (accessed: June 27, 2023).
 67. FDA (2018) Summary Basis for Regulatory Action. <https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/May-3-2018-Summary-Basis-for-Regulatory-Action---ANDEXXA.pdf> (accessed: June 27, 2023).
 68. Cuker A, Burnett A, Triller D, et al. Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. *Am J Hematol.* 2019; 94(6): 697–709, doi: [10.1002/ajh.25475](https://doi.org/10.1002/ajh.25475), indexed in Pubmed: 30916798.
 69. Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. *Blood Adv.* 2018; 2(22): 3257–3291, doi: [10.1182/bloodadvances.2018024893](https://doi.org/10.1182/bloodadvances.2018024893), indexed in Pubmed: 30482765.
 70. Christensen H, Cordonnier C, K orv J, et al. European Stroke Organisation guideline on reversal of oral anticoagulants in acute intracerebral haemorrhage. *Eur Stroke J.* 2019; 4(4): 294–306, doi: [10.1177/2396987319849763](https://doi.org/10.1177/2396987319849763), indexed in Pubmed: 31903428.
 71. Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol.* 2020; 76(5): 594–622, doi: [10.1016/j.jacc.2020.04.053](https://doi.org/10.1016/j.jacc.2020.04.053), indexed in Pubmed: 32680646.
 72. Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation. *Chest.* 2018; 154(5): 1121–1201, doi: [10.1016/j.chest.2018.07.040](https://doi.org/10.1016/j.chest.2018.07.040).
 73. Baugh CW, Levine M, Cornutt D, et al. Anticoagulant reversal strategies in the emergency department setting: recommendations of a multidisciplinary expert panel. *Ann Emerg Med.* 2020; 76(4): 470–485, doi: [10.1016/j.annemergmed.2019.09.001](https://doi.org/10.1016/j.annemergmed.2019.09.001), indexed in Pubmed: 31732375.
 74. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol.* 2019; 74(1): 104–132, doi: [10.1016/j.jacc.2019.01.011](https://doi.org/10.1016/j.jacc.2019.01.011), indexed in Pubmed: 30703431.
 75. Chao TF, Joung B, Takahashi Y, et al. 2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation. *J Arrhythm.* 2021; 37(6): 1389–1426, doi: [10.1002/joa3.12652](https://doi.org/10.1002/joa3.12652), indexed in Pubmed: 34887945.
 76. Steiner T, Unterberg A. Treatment of spontaneous intracerebral bleeding, S2k guidelines, 2021, in: German Society for Neurology (Ed.), *Guidelines for Diagnostics and Therapy in Neurology.* <https://dgn.org/leitlinien/> (accessed: October 6, 2022).
 77. Ono K, Iwasaki YK, Akao M, et al. JCS/JHRS 2020 guideline on pharmacotherapy of cardiac arrhythmias. *Circ J.* 2022; 86(11): 1790–1924, doi: [10.1253/circj.CJ-20-1212](https://doi.org/10.1253/circj.CJ-20-1212), indexed in Pubmed: 35283400.
 78. Carballo  lvarez F, Albillos Mart nez A, Llamas Silero P, et al. Consensus document of the Spanish Society of Digestive Diseases and the Spanish Society of Thrombosis and Haemostasis on massive nonvariceal gastrointestinal bleeding and direct-acting oral anticoagulants. *Rev Esp Enferm Dig.* 2022; 114(7): 375–389, doi: [10.17235/reed.2022.8920/2022](https://doi.org/10.17235/reed.2022.8920/2022), indexed in Pubmed: 35686480.